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Alzheimer's disease（AD） is the most common form of dementia in elderly 
persons which is marked by a decline in memory and cognitive performance. In 
addition, AD is associated with the deterioration of language as well as defects in 
visual and motor coordination, and eventual death. The pathophysiology of AD 
includes the accumulation of extracellular plaques in the brain containing the 
amyloid-β (Aβ) and intracellular neurofibrillary tangles of hyperphosphorylated tau 
protein. By 2050, the prevalence of AD is projected to increase to 60 million in the 
world. Epidemiological studies have consistently shown that the incidence of AD is 
reduced in smokers relative to nonsmokers. However, the mechanisms that contribute 
to this effect still remain to be elucidated. Early growth response gene 1 (EGR-1) 
plays an important role in promoting cell growth, differentiation, oxidative stress, 
apoptosis and ionizing radiation, but its function in AD remains unclear. 
The techniques of western blotting and PCR, also with other molecular biology 
techniques were used to study mainly in SH-SY5Y cells. In the present study, we 
show that nicotine (10-6 M) could activate EGR-1 in concentration-dependent pathway 
and in time course in the protein and transcription level. What is more, 
nicotine-mediated activation of EGR-1 by MAPK/ERK signaling pathway partially 
via the activation of α7 nAChR in the further study. When we knock down the nAchR 
α7, the nicotine-mediated activation of MAPK/ERK/EGR-1 pathway was partly 
blocked. We found that the percentage of apoptotic cells was significantly increased 
and the cellular viability was decreased when treated by 10-6 M Aβ25-35 by Flow 
CytoMeter and MTT, The effect of Aβ25-35 was attenuated when the cells was treated 
by nicotine. The early apoptotic cells were 13.25% when treated with Aβ compared to 
the control of 6.1%. EGR-1 up-regulated cyclinD1 and its phosphorylation in Thr286 
was also increased when EGR-1 was activated, when over-expressed or interfering the 
gene EGR-1, we got the similar results, it may be one of the molecular mechanisms 
why nicotine attenuates Aβ25-35 induced neurotoxicity in SH-SY5Y cells.  
Our results show that EGR-1 is an important zinc finger transcription factor in 
AD. 
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积（图 1.1b）并伴随着大脑中特定位置神经元及突触的丢失（图 1.2）[5-7]。 
1. 阿尔兹海默病的概述 
     (a)                             (b) 
  
 
图 1.1 阿尔兹海默病患者大脑中两个的病理特征：(a) 阿尔兹海默病患者大脑中
的神经纤维缠结图示，使用抗Tau蛋白的PHF抗体免疫染色，图中标尺为 62.5μm；
(b) 阿尔兹海默病患者大脑中淀粉样斑图示，图中标尺为 125μm； 
Fig. 1.1 Tangles and Plaques in the AD brain. (a) A representative microphotograph of 
neurofibrillary tangles. Tangles were visualized by immunostaining with an anti-PHF1 
specific antibody. Scale bar: 62.5 μm. (b) A representative microphotograph of 
amyloid plaques in the AD brain. Scale bar: 125 μm. 
1.1 阿尔兹海默病的病理特征 




























图 1.2 正常人大脑与阿尔兹海默病人大脑比较。（a）正常人大脑与 AD 人脑比较；
（b）；正电子发射断层扫描下的正常人脑和 AD 人脑比较。 
Fig.1.2 (a) Compared with the brain of a healthy person and the brain of an 
Alzheimer's disease patient. (b) Positron emission tomography (Pet) images of the 







1.1.2.1 淀粉样前体蛋白 APP 
淀粉样前体蛋白( amyloid precursor protein, APP)是一种含有 695 个氨基酸的


















(β-amyloid, Aβ) 而广受关注。大部分淀粉样前体蛋白 APP 在健康人的大脑中通
常是以一种“非淀粉样蛋白途径”降解的，淀粉样前体蛋白 APP 在 α 分泌酶的
作用下，在淀粉样蛋白 Aβ的区将淀粉样蛋白 APP 分割为两部分，即分泌的外功
能片段 sAPPα 和羧基末端，羧基末端进一步被γ分泌酶分解成更小的可被逐步
降解的片段。淀粉样前体蛋白 APP 还有另外一个降解途径，经细胞体内的 β 分
泌酶和γ分泌酶逐步降解，通过复杂的水解途径分泌产生多种片断并最终形成淀
粉样蛋白 Aβ（如图 1.4）[5]。APP 基因与淀粉样前体类蛋白基因 1、2 ( amyloid 
precursor like protein, APLP1、APLP2) 一起构成 APP 基因家族，APP 基因转录
后通过不同的剪接形式, 产生几种不同的亚型，分别含有 695 到 770 个氨基酸，
其中较为主要的三个亚型是 APP770、APP751 和 APP695，APP695 在脑组织中
特异性表达，且其表达量远远高于 APP770 和 APP751，因此在阿尔兹海默病的
研究中 APP695 为主要的研究对象[12]。 
 
图 1.3 APP 剪切示意图：Aβ蛋白区域用红色特异性标记出来，每一个酶只对应
一个酶切位点，EC 代表细胞外；TM 代表细胞膜；IC 代表细胞内。 
Fig 1.3 The diagram of APP Processing Aβ domain is highlighted in red. For 
simplicity, only one cleavage site is shown for each enzyme. EC: extracellular; TM: 
transmembrane; IC: intracellular. 
1.1.2.2 淀粉样蛋白 Aβ 
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